肿瘤坏死因子-α(TNF-α)与肥胖

肿瘤坏死因子 ( Tumor Necrosis Factor,TNF)包括由活化的单核 /巨噬细胞产生的TNF- α和由活化的 T淋巴细胞产生的 TNF- β两种。二者在细胞来源、相对分子量、等电点、糖含量等方面有很大差别。 TNF-α是一种具有多种生物学活性的细胞因子 ,由 1 40 - 1 5 0个氨基酸残基组成 ,其中有两个反平行β片层 ,每个β片层有 5个β折叠。它由 TNFRI和 TNFRII两种受体组成 ,二者胞内结构区的同源性极低 ( 2 7% ) ,可能启动不同的生物学反应。研究发现TNF- α是与肥胖相关的蛋白质之一 ,对脂肪代谢具有重要调节作用。TNF- α通过抑制进食、增加机体产热量 ;促进脂肪分解、抑制脂肪合成 ;诱导产生瘦素 ;引起胰岛素抑制、抑制前脂肪细胞分化 ;诱导前脂肪细胞及脂肪细胞凋亡等作用调节脂肪代谢和能量平衡。同时 ,TNF- α在肥胖动物或人的脂肪组织中过量表达 ,也会给人和动物机体带来很多副作用     

Effect of resveratrol on level of brain-derived neurotrophic factor in hippocampus of obese rats induced by ovariectomy and high-fat diet

AIM：To explore the effects of resveratrol on the level of brain-derived neurotrophic factor (BDNF) and the mRNA expression of estrogen receptor α (ERα) and estrogen receptor β (ERβ) in hippocampus of obese rats induced by ovariectomy and high-fat diet. METHODS：Fifty female Wistar rats, aged 3 months, were randomly divided into 5 groups: control (C) group, sham operation plus high-fat diet (H) group, ovariectomy plus normal diet (O) group, ovariectomy plus high-fat diet (O+H) group, and ovariectomy plus high-fat diet and treated with resveratrol (40 mg·kg-1·d-1) (O+H+R) group. Three months later, the blood was collected from the femoral artery to detect the serum concentrations of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and estradiol (E2). The mRNA expression of ERα, ERβ and BDNF in the hippocampus was determined by real-time PCR. The protein level of BDNF in hippocampal tissues was detected by ELISA and Western blotting. RESULTS：Compared with C group, the serum levels of TC and LDL-C in H group were increased, and the hippocampal level of BDNF was decreased. The rats in O group had higher concentration of serum TC, and lower levels of serum E2 and the mRNA expression of ERα, ERβ and BDNF in the hippocampus than those in C group. Compared with C,H and O groups, the level of serum TC was higher, and the level of serum E2 and the expression of BDNF in the hippocampus was lower in O+H group. The mRNA expression of ERα and ERβ in hippocampus was also reduced as compared with C group and H group. After treated with resveratrol, the rats in O+H+R group showed lower level of serum TC, and higher levels of serum E2, hippocampal BDNF and mRNA expression of ERα and ERβ than those in O+H group. CONCLUSION：Ovariectomy combined with high-fat diet decreases the mRNA expression of ERαand ERβ and the level of BDNF in the rat hippocampus. Resveratrol improves the blood lipid metabolism and up-regulates the mRNA expression of ERα/ERβ and the level of BDNF in the hippocampus in obese rats induced by ovariectomy and high-fat diet.     

Role of uncoupling protein 1 in the anti-obesity effect of beta3-adrenergic agonist in the dog

We have reported that chronic treatment with beta3-adrenoceptor agonists reduces body fat content and induces the expression of mitochondrial thermogenic uncoupling protein 1 (UCP1) in adipose tissue in the dog. To evaluate the role of UCP1 in the anti-obesity effect of the agonists, we isolated adipocytes from subcutaneous fat pad of beagles before and after a 2-week treatment with AJ-9677, a specific beta3-adrenoceptor agonist, and examined their thermogenic activity in vitro. Histological and protein analysis revealed that adipose tissues before the treatment were composed of unilocular cells filled with a single large droplet, while the tissues after the treatment contained many smaller and some multilocular adipocytes expressing UCP1 and abundant mitochondrial proteins. Before the treatment, oxygen consumption rate was very low and did not change even when the cells were stimulated by AJ-9677. Two-week AJ-9677 treatment increased basal oxygen consumption rate by 7-fold, and produced a clear responsiveness to AJ-9677 stimulation. Thus, chronic treatment with AJ-9677 induced UCP1 in adipocytes, where oxygen consumption increased in response to AJ-9677 stimulation. It was suggested that UCP1-dependent energy expenditure in adipose tissue contributes to the anti-obesity effect of beta3-adrenoceptor agonist in dogs.     

Birth weight and gender determine expression of adipogenic, lipogenic and adipokine genes in perirenal adipose tissue in the young adult sheep

Epidemiological studies have demonstrated that low birth weight is associated with an increased incidence of visceral obesity and metabolic disorders in later life. In the present study, we have determined the impact of birth weight and gender on gene expression in visceral adipose tissue (VAT) in the young adult sheep. Lambs (n=19, birth weight range 2.6-7.55 kg) were born at term and growth monitored for 22.4+/-0.2 weeks, when body composition was determined by Dual X-ray Absorptiometry (DXA) and samples of VAT and subcutaneous (SCAT) adipose tissue collected. Plasma samples were collected at post-mortem for the determination of free fatty acids (FFA), glucose and insulin concentrations. Peroxisome-Proliferator Activated Receptor-gamma (PPARgamma), glycerol-3-phosphate dehydrogenase (G3PDH), lipoprotein lipase (LPL), adiponectin and leptin mRNA expression was determined by qRT-PCR. Fractional growth rate in postnatal weeks 1-3 was inversely related to birth weight in both males and females (R2=0.22, P<0.05, n=19). PPARgamma mRNA expression in VAT, but not SCAT, was inversely related to birth weight (R2=0.60, P<0.01, n=18). In males, but not females, PPARgamma mRNA in VAT was directly related to G3PDH mRNA expression (R2=0.69, P<0.01, n=9). Plasma FFA concentrations were inversely related to birth weight in both males and females (R2=0.22, P<0.05, n=19). These findings demonstrate that low birth weight is associated with an increased expression of a key adipogenic factor in visceral adipose tissue in young adulthood. In males, this is associated with an increased expression of lipogenic genes, and this may contribute to the increased propensity for visceral obesity in low birth weight males compared to females.     

Development of a feline proinsulin immunoradiometric assay and a feline proinsulin enzyme-linked immunosorbent assay (ELISA): a novel application to examine beta cell function in cats

The prevalence of feline diabetes mellitus has increased several-fold over the last three decades. In humans, progression from obesity to diabetes is marked by changes in the release of proinsulin. A specific proinsulin (FPI) assay has not been available to examine similar changes in cats. The goal of this study was to develop a proinsulin assay for the analysis of beta cell function in cats. Monoclonal antibodies were developed against recombinant FPI and used in a two-site sandwich immunoradiometric assay (IRMA) and enzyme-linked immunosorbent Assay (ELISA). The antibody pair had negligible cross-reactivity with bovine insulin and feline C-peptide. The working range was 11-667pmol/L for the IRMA and 11-1111pmol/L for the ELISA. An intravenous glucose tolerance test was performed in six long-term obese and six lean adult healthy cats and serum glucose, insulin, and FPI concentrations were determined. The proinsulin and insulin secretion pattern in response to glucose was significantly different between lean and obese cats but the pattern was similar within a group. Both groups had similar baseline proinsulin/insulin ratios; however, obese cats showed a significantly higher proinsulin/insulin ratio during the first 15min of the IVGTT and a much lower ratio during the last 30min suggesting a time-delayed adjustment to the increased insulin demand. In conclusion, we report the development and validation of an IRMA and an ELISA for FPI. This novel assay is useful to elucidate FPI secretion and can be used similar to a C-petide assay to evaluate residual beta cell function in cats.     

Association of body weight and body condition with survival in dogs with heart failure

BACKGROUND: Obesity is a risk factor for cardiovascular disease in people, but overweight and obese human heart failure patients have improved survival compared with normal--or underweight controls--the obesity paradox. The purpose of this study was to determine if there is an association of body weight and body condition with survival in dogs with heart failure. HYPOTHESIS: That body condition and changes in body weight are predictors of survival in dogs with heart failure. ANIMALS: One hundred and eight dogs with heart failure (International Small Animal Cardiac Health Council stages 2, 3a, or 3b) secondary to dilated cardiomyopathy or chronic valvular disease. METHODS: Medical records were reviewed, and data regarding initial body weight and body condition score (BCS), subsequent changes in body weight, and treatment were collected. Survival times were determined for dogs that were discharged from the hospital and lived >24 hours. RESULTS: Survival was significantly different between dogs that gained, lost, or maintained body weight over the course of their disease (P= .04), with dogs that gained weight surviving the longest. BCS and medications were not significantly associated with survival time; however, n-3 fatty acid intake was associated with longer survival time (P= .009). CONCLUSIONS AND CLINICAL IMPORTANCE: These results suggest that changes in body weight might be an important consideration in the survival of dogs with heart failure.